PathAI

PathAI applies machine learning to anatomic pathology, improving diagnostic accuracy and powering biomarker analysis for drug development.

Overview

PathAI builds algorithms that assist pathologists at the microscope and in digital pathology workflows, reducing variability in how tissue is scored. Its AISight digital pathology platform gives labs an image management system designed for AI from the ground up. On the pharma side, PathAI runs pathology work for clinical trials, using quantitative image analysis to measure treatment response. The company works with hundreds of labs and most of the top biopharma firms to standardize how tissue endpoints are read.

Key Features

• AI-assisted scoring for tumor type, grade and biomarker status
• AISight image management for whole-slide digital pathology
• Quantitative tissue analysis for clinical trial endpoints
• Lab workflow tools that prioritize and route cases
• Model development services for partner diagnostic programs
• Quality-control dashboards that track concordance and reader variability

Pricing

PathAI prices its products and trial services through enterprise contracts with laboratories and pharmaceutical sponsors. Cost depends on volume, modules and the level of study support.

Who Is It For

Anatomic pathology labs modernizing their workflows and pharma teams that need rigorous, quantified pathology reads for trials. It suits organizations standardizing diagnostic quality across sites.

FAQ

Is PathAI free to use?

No. PathAI is an enterprise platform with negotiated pricing for labs and sponsors.

Does PathAI offer an API?

Yes. Integration options exist for lab information systems and scanner hardware, and partners can build on PathAI analysis services.

How does PathAI compare to alternatives?

PathAI differentiates by covering both the clinical lab workflow and trial pathology services, whereas most competitors focus on only one side.

Practical Use Cases

Reference labs use PathAI’s algorithms to standardize biomarker scoring across sites, reducing inter-observer variability in routine reads. Biopharma sponsors engage PathAI to run pathology endpoints for clinical trials, where quantitative tissue analysis improves sensitivity over manual scoring. Hospital labs deploy AISight to manage whole-slide images and route complex cases to subspecialists. Quality teams monitor concordance dashboards to catch drift in reads and target training where variability appears.

Limitations & Alternatives

PathAI’s deepest value shows in organizations with digital pathology infrastructure and trial work; small glass-slide practices may not realize the benefit. Trial services require project scoping and budget, and algorithm deployment must fit local regulatory pathways. Paige and Ibex compete in clinical pathology AI, while CROs like Labcorp offer overlapping trial pathology services.

Integrations & Deployment

PathAI’s AISight platform integrates with scanners, LIS and hospital systems so whole-slide images and AI results flow into routine pathology operations. Deployments begin with workflow mapping — accessioning, reading, sign-out — followed by validation studies on local case material before clinical use. Trial pathology engagements run as managed projects with defined milestones for tissue handling, analysis and reporting. Cloud hosting supports remote sign-out and collaboration between sites, while quality dashboards feed into laboratory QA programs. PathAI’s teams support the change management side too, since AI-assisted reading shifts how pathologists spend attention across the worklist.